The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).
Tetsuya Mitsudomi
Consultant or Advisory Role - AstraZeneca
Honoraria - AstraZeneca; Sanofi
Expert Testimony - AstraZeneca (U)
Satoshi Morita
Honoraria - AstraZeneca
Yasushi Yatabe
No relevant relationships to disclose
Shunichi Negoro
Honoraria - AstraZeneca; Sanofi
Research Funding - AstraZeneca
Isamu Okamoto
No relevant relationships to disclose
Takashi Seto
Honoraria - AstraZeneca; Sanofi
Research Funding - AstraZeneca
Miyako Satouchi
Honoraria - AstraZeneca; Sanofi
Hirohito Tada
Honoraria - Sanofi
Tomonori Hirashima
No relevant relationships to disclose
Kazuhiro Asami
No relevant relationships to disclose
Nobuyuki Katakami
Honoraria - AstraZeneca; Bristol-Myers Squibb; Sanofi
Research Funding - AstraZeneca; Bristol-Myers Squibb; Sanofi
Minoru Takada
No relevant relationships to disclose
Hiroshige Yoshioka
Honoraria - AstraZeneca; Sanofi
Kazuhiko Shibata
Honoraria - AstraZeneca
Shinzoh Kudoh
No relevant relationships to disclose
Eiji Shimizu
No relevant relationships to disclose
Hiroshi Saito
Honoraria - AstraZeneca; Sanofi
Shinichi Toyooka
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Kazuhiko Nakagawa
Honoraria - AstraZeneca; Bristol-Myers Squibb; Sanofi
Masahiro Fukuoka
Honoraria - AstraZeneca